Ufp Technologies Inc (NASDAQ: UFPT)

Sector: Healthcare Industry: Medical Devices CIK: 0000914156
Market Cap 1.89 Bn
P/B 4.69
P/E 28.23
P/S 3.17
ROIC (Qtr) 12.89
Div Yield % 0.00
Rev 1y % (Qtr) 6.47
Total Debt (Qtr) 165.51 Mn
Debt/Equity (Qtr) 0.41
Add ratio to table...

About

UFP Technologies Inc., or UFPT, operates in the medical technology (MedTech) industry, a large and growing market with diverse applications. The company specializes in designing and manufacturing custom solutions for medical devices, sterile packaging, and other highly engineered custom products. UFPT generates revenue through the sale of custom-engineered products, including protective drapes for robotic surgery, single-patient use surfaces, advanced wound care, infection prevention, disposables for surgical and endoscopic procedures, packaging...

Read more

Investment thesis

Bull case

  • Strong operating cash flow of 99.49M provides robust 0.60x coverage of total debt 165.51M, indicating excellent debt servicing capability and financial flexibility.
  • Operating cash flow of 99.49M provides strong 11.69x coverage of stock compensation 8.51M, indicating sustainable incentive practices.
  • Robust free cash flow of 87.47M exceeds capital expenditure of 12.02M by 7.28x, indicating strong organic growth funding capability.
  • Tangible assets of 312.26M provide exceptional 64.61x coverage of deferred revenue 4.83M, showing strong service capability backing.
  • Retained earnings of 357.25M provide full 2.41x coverage of long-term debt 148.06M, indicating strong internal capital position.

Bear case

  • Operating cash flow of 99.49M barely covers its investment activities of (27.62M), with a coverage ratio of -3.60, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • With cash reserves of 18.23M against inventory of 86.15M, the 0.21 cash-to-inventory ratio suggests potential liquidity risks if inventory turnover slows, particularly concerning given current supply chain volatilities.
  • Cash reserves of 18.23M provide limited coverage of acquisition spending of (15.77M), which is -1.16x, suggesting aggressive expansion might strain liquidity if market conditions deteriorate.
  • Free cash flow of 87.47M represents just -1.33x of debt issuance (65.94M), suggesting concerning reliance on leverage rather than internal cash generation for growth.
  • Tax assets of 1.89M provide limited offset against tax liabilities of 7.79M, which is 0.24x, indicating potential future cash flow pressure from tax obligations.

Customer Breakdown of Revenue (2024)

Product and Service Breakdown of Revenue (2024)

Peer comparison

Companies in the Medical Devices
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ABT Abbott Laboratories 173.80 Bn 32.73 5.47 12.94 Bn
2 SYK Stryker Corp 141.15 Bn 43.48 5.62 15.86 Bn
3 MDT Medtronic plc 123.47 Bn 25.92 3.55 29.10 Bn
4 BSX Boston Scientific Corp 112.80 Bn 38.92 5.62 11.44 Bn
5 EW Edwards Lifesciences Corp 45.66 Bn 33.38 7.76 0.70 Bn
6 DXCM Dexcom Inc 27.52 Bn 32.91 5.90 1.34 Bn
7 STE STERIS plc 24.13 Bn 34.08 4.14 2.05 Bn
8 PODD Insulet Corp 17.33 Bn 70.38 6.87 1.01 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 3.16 2.13
EV to Cash from Ops. EV/CFO 20.71 2.75
EV to Debt EV to Debt 12.45 17.25
EV to EBIT EV/EBIT 22.08 2.89
EV to EBITDA EV/EBITDA 18.24 4.53
EV to Free Cash Flow [EV/FCF] EV/FCF 23.56 29.36
EV to Market Cap EV to Market Cap 1.09 25.09
EV to Revenue EV/Rev 3.45 32.80
Price to Book Value [P/B] P/B 4.69 4.73
Price to Earnings [P/E] P/E 28.23 -2.04
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 40.22
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 1.59
Dividend per Basic Share Div per Share (Qtr) 0.00 0.10
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.37
Interest Coverage Int. cover (Qtr) 8.29 196.93
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) 4.64 -152.08
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 11.43 8,476.58
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 -0.44
EBIAT Growth (1y) % EBIAT 1y % (Qtr) 30.04 -792.16
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 32.41 3.79
EBIT Growth (1y) % EBIT 1y % (Qtr) 30.97 -301.80
EBT Growth (1y) % EBT 1y % (Qtr) 24.69 -121.44
EPS Growth (1y) % EPS 1y % (Qtr) 23.16 -87.51
FCF Growth (1y) % FCF 1y % (Qtr) 106.95 10.43
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 30.38 38.21
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.92 0.55
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.02
Cash Ratio Cash Ratio (Qtr) 0.22 1.80
Current Ratio Curr Ratio (Qtr) 2.41 4.18
Debt to Equity Ratio Debt/Equity (Qtr) 0.41 1.20
Interest Cover Ratio Int Coverage (Qtr) 8.29 196.93
Times Interest Earned Times Interest Earned (Qtr) 8.29 196.93
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) 18.80 -2,396.63
EBIT Margin % EBIT Margin % (Qtr) 15.61 -2,478.60
EBT Margin % EBT Margin % (Qtr) 13.73 -2,690.42
Gross Margin % Gross Margin % (Qtr) 28.50 30.80
Net Profit Margin % Net Margin % (Qtr) 11.20 -2,821.53